Compare AbbVie Inc (ABBV) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Spotify Technology — how do they compare? AbbVie Inc trades at $248.25 (market cap $441.94B), while Spotify Technology trades at $492.56 (market cap $103.00B). The key difference: AbbVie Inc is far larger — about 4.3× Spotify Technology's market cap, and AbbVie Inc pays a 2.77% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| ABBV | SPOT | |
|---|---|---|
Market Cap | $441.94B | $103.00B |
Sector | Health | Media |
52-Week High | $263.58 | $738.53 |
52-Week Low | $197.38 | $412.75 |
Enterprise Value | $506.19B | $92.70B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Spotify (SPOT) trades at $511.82, up 4.85% with a bullish technical outlook. The company reported strong Q2 2026 results with revenue growth and record gross margins, though earnings missed estimates due to higher AI and marketing costs. Analyst consensus is bullish with a $598.20 price target, supported by 61.5% buy ratings. Recent news highlights Spotify's initiative to label AI-generated artists, enhancing platform transparency.
The outlook remains positive with robust subscriber growth and monetization efforts, but risks include competitive pressures and cost management. Upside potential exists if execution continues, while misses on user growth or margin targets could weigh on the stock. The current valuation reflects optimism for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
